BioNTech (Mfg Services) vs Evonik Health Care: CDMO Comparison
How does BioNTech (Mfg Services) compare to Evonik Health Care for mRNA/LNP manufacturing?
Side-by-side comparison of BioNTech (Mfg Services) and Evonik Health Care on independent FDA inspections, EMA and MHRA GMP certificates, clinical-program activity, and CDMO Signal Score. Data sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.
Key differences
- Evonik Health Care has FDA inspections on record (2); BioNTech (Mfg Services) does not yet appear in the FDA inspection database.
- Both maintain clean enforcement records — no FDA OAI classifications or warning letters on file for either CDMO.
- BioNTech (Mfg Services) holds 8 active EMA GMP certificates; Evonik Health Care does not appear in EudraGMDP.
- Evonik Health Care maintains 2 MHRA / UK GMP certificates; BioNTech (Mfg Services) does not.
- BioNTech (Mfg Services) appears as a manufacturing partner on more matched clinical programs (28 vs 0) — a broader sponsor book.
On a 13-modality CDMO landscape, both BioNTech (Mfg Services) and Evonik Health Care qualify as mRNA/LNP manufacturers; BioNTech (Mfg Services) carries the higher composite Signal Score for mRNA/LNP programs in this comparison.
What to evaluate for mRNA/LNP programs
Both BioNTech (Mfg Services) and Evonik Health Care qualify as mRNA/LNP CDMOs. When choosing between them for mRNA/LNP programs, weigh these four dimensions specifically — each carries through to the side-by-side scorecard above.
IVT mRNA synthesis
Assess in-vitro transcription scale, capping strategy (co-transcriptional vs enzymatic), and template sourcing. These drive yield, purity, and cost.
LNP formulation
LNP encapsulation via microfluidics determines potency and tolerability. Confirm lipid sourcing, formulation freedom-to-operate, and particle-size control.
Plasmid / starting material
mRNA needs a DNA template. Check whether the CDMO supplies GMP plasmid in-house or coordinates a plasmid CDMO — it affects timelines.
Cold chain & stability
mRNA-LNP products are temperature-sensitive. Evaluate frozen storage, fill-finish, and the stability program.
Frequently asked: BioNTech (Mfg Services) vs Evonik Health Care
How does BioNTech (Mfg Services) compare to Evonik Health Care for mRNA/LNP manufacturing?
On CDMO Signal's composite Signal Score, BioNTech (Mfg Services) is 82/100 and Evonik Health Care is 82/100; BioNTech (Mfg Services) has 0 FDA inspections on record vs 2 for Evonik Health Care; European coverage is 8 active EMA+MHRA certificates for BioNTech (Mfg Services) vs 2 for Evonik Health Care. Both are tracked in the CDMO Signal directory as mRNA/LNP CDMOs. The scorecard above breaks down every metric side by side — use it alongside each CDMO's individual profile for the full regulatory and clinical footprint.
Which has the stronger FDA inspection record, BioNTech (Mfg Services) or Evonik Health Care?
Both BioNTech (Mfg Services) and Evonik Health Care maintain clean enforcement records on file — no FDA warning letters and no OAI classifications. BioNTech (Mfg Services) has 0 FDA inspections on record; Evonik Health Care has 2.
How do BioNTech (Mfg Services) and Evonik Health Care compare on European GMP coverage?
BioNTech (Mfg Services) holds 8 active EMA GMP certificates and 0 MHRA / UK certificates. Evonik Health Care holds 0 active EMA GMP certificates and 2 MHRA / UK certificates. Use these counts as a proxy for the breadth of each CDMO's European regulatory footprint.
Which is more active in clinical-stage manufacturing — BioNTech (Mfg Services) or Evonik Health Care?
BioNTech (Mfg Services) is matched to 28 ClinicalTrials.gov records as a manufacturing partner; Evonik Health Care is matched to 0. Higher counts indicate broader sponsor exposure but say nothing about approved-product track record — pair this number with each CDMO's profile page for context.
Which is better for mRNA/LNP manufacturing — BioNTech (Mfg Services) or Evonik Health Care?
Both BioNTech (Mfg Services) and Evonik Health Care are tagged as mRNA/LNP CDMOs in our directory, so both are credible options for mRNA/LNP programs. The most important differentiator for mRNA/LNP selection is typically ivt mrna synthesis: Assess in-vitro transcription scale, capping strategy (co-transcriptional vs enzymatic), and template sourcing. These drive yield, purity, and cost. Review each CDMO's profile and inspection record before shortlisting.
Use the free AI matchmaker to weigh both against your specific requirements — capacity, modality, regulatory record, geography — and surface other qualified options.
Find & compare CDMOs →